Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gross

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
Therapeutic Drug Monitoring|July 2, 2010
Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and functionDarinka T Petrova, Gunnar Brandhorst, Franziska Brehmer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 9, 2007
Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndromeMarie-Louise Koepke, Manfred Weber, Eckhard Schulze-Lohoff, et al.
Journal of Proteome Research|October 22, 2015
Preclinical Alterations in the Serum of COL(IV)A3(-)/(-) Mice as Early Biomarkers of Alport SyndromePetra Muckova, Sindy Wendler, Diana Rubel, et al.
ISRN Pediatrics|July 20, 2012
Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric PatientsOliver Gross, Tim Friede, Reinhard Hilgers, et al.
Pediatric Nephrology (Berlin, Germany)|March 27, 2021
Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndromeYanqin Zhang, Jan Böckhaus, Fang Wang, et al.
Kidney International|July 15, 2005
Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688Oliver Gross, Marie-Louise Koepke, Bogdan Beirowski, et al.
Kidney International|October 22, 2010
Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte lossMi Ryu, Onkar P Kulkarni, Ewa Radomska, et al.
World Journal of Urology|June 29, 2018
Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancerAshkan Mortezavi, Souzan Salemi, Benedikt Kranzbühler, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 21, 2007
Inner ear defects and hearing loss in mice lacking the collagen receptor DDR1Angela M Meyer zum Gottesberge, Oliver Gross, Ursula Becker-Lendzian, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 8, 2013
Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosisDiana Rubel, Johanna Stock, Ayse Ciner, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Therapeutic Drug Monitoring|July 2, 2010
Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and functionDarinka T Petrova, Gunnar Brandhorst, Franziska Brehmer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 9, 2007
Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndromeMarie-Louise Koepke, Manfred Weber, Eckhard Schulze-Lohoff, et al.
Journal of Proteome Research|October 22, 2015
Preclinical Alterations in the Serum of COL(IV)A3(-)/(-) Mice as Early Biomarkers of Alport SyndromePetra Muckova, Sindy Wendler, Diana Rubel, et al.
ISRN Pediatrics|July 20, 2012
Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric PatientsOliver Gross, Tim Friede, Reinhard Hilgers, et al.
Pediatric Nephrology (Berlin, Germany)|March 27, 2021
Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndromeYanqin Zhang, Jan Böckhaus, Fang Wang, et al.
Kidney International|July 15, 2005
Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688Oliver Gross, Marie-Louise Koepke, Bogdan Beirowski, et al.
Kidney International|October 22, 2010
Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte lossMi Ryu, Onkar P Kulkarni, Ewa Radomska, et al.
World Journal of Urology|June 29, 2018
Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancerAshkan Mortezavi, Souzan Salemi, Benedikt Kranzbühler, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 21, 2007
Inner ear defects and hearing loss in mice lacking the collagen receptor DDR1Angela M Meyer zum Gottesberge, Oliver Gross, Ursula Becker-Lendzian, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 8, 2013
Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosisDiana Rubel, Johanna Stock, Ayse Ciner, et al.
Pageof 15